Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients

Diarrhea Clinical Trial

Official title:

Double Blind, Randomized, Placebo Controlled Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics in the Prophylaxis Of Diarrhea In Adult Patients Who Already Initiated An Oral Antibiotic Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06283784
• Other study ID #: YOVIS Capsules
• Status: Completed
• Phase: N/A
• Start date: September 5, 2021
• Est. completion date: May 18, 2022

Study information

• Verified date: March 2024
• Source: Biofarma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double blind, randomized, placebo-controlled study. One-hundred subjects are randomized to receive either YOVIS or placebo over a period of 10 days. The purpose is to determinate the efficacy of the treatment in subjects treated with antibiotic therapy, by measuring occurrence of Antibiotic Associated Diarrhoea (AAD) from baseline to the end of the observation period (28±2 days)

Description:

AAD is defined as clinically unexplained diarrhea that occurs in connection with antibiotic administration. Any antibiotic could potentially cause AAD, but broad-spectrum antibiotics that predominantly target anaerobes and are poorly absorbed, such as clindamycin, cephalosporins (cefixime and ceftriaxone), and amoxicillin-clavulanate, have a higher AAD incidence (Turck D, 2003). It has been reported that the highest rates of AAD in 650 pediatric cases were associated with amoxicillin/clavulanate (23%), penicillin A or M (11%) and erythromycin (16%). In the present trial, adult population already under antibiotic therapy with ampicillin/amoxicillin, cephalosporins and clindamycin, will be selected, in order to capture the highest possible diarrhea events, with a limited number of subjects. YOVIS, the Investigational Food Supplement (IFS), is an oral formulation (capsules) containing definite mix of live probiotics already marketed by Alfa-Sigma as food supplement since September 2017. Placebo is an oral formulation of inert capsules. Placebo and YOVIS are identical in shape, size, colour and taste. One-hundred (100) subjects will be randomized to receive either YOVIS or placebo (1:1) over a period of 10 days. In case all inclusion/exclusion criteria are met, the subject will be randomized at the baseline visit to one of two masked trial treatments. Further phone contacts are scheduled on day 10±2 and day 21±2, a final visit at site is scheduled on day 28±2. The primary objective of this study is to assess, versus placebo, the efficacy of a 10 days treatment with YOVIS in preventing the incidence of AAD in subjects under antibiotic therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 18, 2022
• Est. primary completion date: November 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Written informed consent, personally signed and dated by the subject.

2. Subjects of both sexes between 18 and 65 years of age (limits included), with no limitation of race.

3. Patients being prescribed or having started an antibiotic therapy with ampicillin/amoxicillin, cephalosporins and clindamycin in the 48h preceding the screening.

4. Antibiotic therapy prescription with a lasting of at least 3 days but no more than 14 days.

5. Subject able to comprehend the full nature and purpose of the study, available to cooperate with the Investigator and to comply with the requirements of the entire study. Exclusion Criteria: Inclusion criteria Subjects will be included in the study if they meet all the following criteria.

1. Written informed consent, personally signed and dated by the subject.

2. Subjects of both sexes between 18 and 65 years of age (limits included), with no limitation of race.

3. Patients being prescribed or having started an antibiotic therapy with ampicillin/amoxicillin, cephalosporins and clindamycin in the 48h preceding the screening.

4. Antibiotic therapy prescription with a lasting of at least 3 days but no more than 14 days.

5. Subject able to comprehend the full nature and purpose of the study, available to cooperate with the Investigator and to comply with the requirements of the entire study. Exclusion Criteria

Subjects will be excluded if they meet any of the following criteria:

1. Pregnant or breast-feeding woman.

2. Known hypersensitivity or allergy to the active ingredients and/or to any component of the probiotic mix.

3. Subject with known food intolerance (eg. milk protein, gluten..)

4. Subject who has taken during the 2 weeks prior to inclusion, who is currently taking or plans to take other orally administered food supplements except the study product

5. Use of antidiarrhoeic drug is forbidden (maintenance of stable and regular treatment started more than 2 weeks before screening visit is allowed)

6. Active diarrhea at the time of the screening visit

7. Non controlled intestinal disease

8. Any antibiotic therapy in the 30 days preceding enrolment

9. Active participation in another clinical study

10. Subject with one or more psychiatric disturbances, such as: alcoholism, substance abuse or dependency disorder, bipolar disorder, schizophrenia, or other personality disorder.

Related Conditions & MeSH terms

• Diarrhea

Intervention

Other:
• Yovis Capsules
Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
• Placebo
Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.

Locations

Country	Name	City	State
Italy	General Practitioner Ambulatory	Sanremo	Italy/Imperia

Sponsors (2)

Lead Sponsor	Collaborator
Biofarma	Hippocrates Research

Country where clinical trial is conducted

Italy, 

References & Publications (16)

Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics. 1999 Nov;104(5):e64. doi: 10.1542/p — View Citation

Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938-56. doi: 10.1080/10408398.2011.619671. — View Citation

Beaugerie L, Petit JC. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):337-52. doi: 10.1016/j.bpg.2003.10.002. — View Citation

Chu W, Lu F, Zhu W, Kang C. Isolation and characterization of new potential probiotic bacteria based on quorum-sensing system. J Appl Microbiol. 2011 Jan;110(1):202-8. doi: 10.1111/j.1365-2672.2010.04872.x. Epub 2010 Oct 18. — View Citation

Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents. 2005 May;25(5):385-91. doi: 10.1016/j.ijant — View Citation

Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol. 2005 Oct;3(10):777-88. doi: 10.1038/nrmicro1273. — View Citation

Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012 May 9;307(18):1959-69. doi: 10.1001/jama — View Citation

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the sco — View Citation

Lee YK, Puong KY, Ouwehand AC, Salminen S. Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. J Med Microbiol. 2003 Oct;52(Pt 10):925-930. doi: 10.1099/jmm.0.05009-0. — View Citation

Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997 Sep;32(9):920-4. doi: 10.3109/00365529709011203. — View Citation

Lui M, Gallo-Hershberg D, DeAngelis C. Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients. Health Qual Life Outcomes. 2017 Dec 22;15(1):249. doi: 10.1186/s12955-017-0794-6. — View Citation

Lukasik J, Guo Q, Boulos L, Szajewska H, Johnston BC. Probiotics for the prevention of antibiotic-associated adverse events in children-A scoping review to inform development of a core outcome set. PLoS One. 2020 May 29;15(5):e0228824. doi: 10.1371/journa — View Citation

Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7(4):e34938. doi: 10.1371/journal.pone.0034938. Epub 2012 Apr 18. — View Citation

Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004 Oct;28(4):405-40. doi: 10.1016/j.femsre.2004.01.003. — View Citation

Turck D, Bernet JP, Marx J, Kempf H, Giard P, Walbaum O, Lacombe A, Rembert F, Toursel F, Bernasconi P, Gottrand F, McFarland LV, Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr G — View Citation

von Ossowski I, Reunanen J, Satokari R, Vesterlund S, Kankainen M, Huhtinen H, Tynkkynen S, Salminen S, de Vos WM, Palva A. Mucosal adhesion properties of the probiotic Lactobacillus rhamnosus GG SpaCBA and SpaFED pilin subunits. Appl Environ Microbiol. 2 — View Citation

* Note: There are 16 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of YOVIS in preventing the incidence of AADD in subjects under antibiotic therapy	The primary objective of this study is to assess, versus placebo, the efficacy of a 10 days treatment with YOVIS in preventing the incidence of AAD in subjects under antibiotic therapy. The incidence of diarrhea in the treatment group will be compared to placebo in the time frame of 28 days.	10 days - 21 days - 28 days
Secondary	Severity and duration of AAD	Cumulated duration of antibiotic-associated diarrhea (AAD) : number of days with diarrhea within the observation period	Time Frame: 28 days
Secondary	Severity and duration of AAD	Cumulative severity of antibiotic-associated diarrhea (AAD): sum of the values (obtained by transformation of Bristol stool form types) of all stools during days with diarrhea (transformation of Bristol scale types is defined: type 1 to 4 = 0; type 5 = 1; type 6 = 2 and type 7 = 3) diarrhea within the observation period	Time Frame: 28 days
Secondary	Evaluation of duration and severity of gastrointestinal symptoms	number of patients with gastrointestinal symptoms in the two groups	28 days
Secondary	Evaluation of duration and severity of gastrointestinal symptoms	cumulative duration with symptoms in the two groups;	28 days
Secondary	Evaluation of duration and severity of gastrointestinal symptoms	the cumulative severity of each symptom	28 days
Secondary	Impact of bowel habits on QoL	assessed trough a 6-item questionnaire self-compiled by the subject at each visit. Quality of Life Questionnaire is compiled. 6 questions from minimum value of 0 (no impact) to 10 (maximum impact) on the quality of life	10-21-28 days
Secondary	Effects of YOVIS, versus placebo, at each visit on the overall health status	assessed trough questions on the general well-being and through physical examination during visits. Questionnaire on the Gatrointestinal syntoms. each question minimum value is 0 (no pain at all) to 10 (maximum intensity of pain)	10-21-28 days
Secondary	Assessment of acceptability, safety and satisfaction grade of YOVIS versus placebo	Patient satisfaction will be evaluated at the end of treatment. The clinician will ask the patient his satisfaction grade compared to her expectation, in a 5-point scale: Not at all Satisfied," "Partly Satisfied," "Satisfied," "More than Satisfied," "Very Satisfied," numbering 1 to 5 as an interval scale.	10 days
Secondary	Global Patient's self-reported acceptance at the end of study	Global patient's acceptance to the treatment will be evaluated at the end of study visit, referred to the whole period, as bad, good, fair, excellent	28 days
Secondary	Global acceptability (investigator) at the end of study	Global investigator acceptance to the treatment will be evaluated at the end of study visit, referred to the whole period, as bad, good, fair, excellent	28 days